Shares of DexCom (DXCM) lost almost 3% on Jun 3, probably due to concerns about a rise in competition for its recently approved Stelo as the FDA approved a competing product.The FDA approval for Stelo in March 2024 looked promising as it was the first and only continuous glucose monitoring (CGM) device to receive approval for its over-the-counter (OTC) availability as a glucose biosensor. Stelo represents a significant opportunity as it can be used to get glucose insights directly on a smartphone without a ...

Innovation is paying off for both of these medical device specialists.Every good thing must come to an end -- and, eventually, the bull market we're experiencing will, too. Long-term investors must prepare for that to happen at some point.One of the best ways to do so is to buy stocks that can perform well through bull runs but can also hold down the fort when things aren't going so well. That's what it takes to deliver market-beating returns over long periods -- corporations that crumble under the pressure ...

Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat.Successful investors think about the future by focusing on what the new opportunities might be. They also pay attention to threats that could emerge that might impact the stocks they own. Sometimes, those threats come out of the blue, but other times, they're identifiable well in advance.If you own shares of Abbott (ABT -1.20%) or DexCom (DXCM 0.20%), there's a looming threat to know about. It's ...

In a recent deep-dive research report on the state of the MedTech (medical technology) sector, Oppenheimer highlighted the potential of artificial intelligence (AI) in the sector, noting its capacity to save an estimated $200 billion to $300 billion annually through enhanced workflow management. Inspired by these findings, this article explores the three best MedTech stocks to buy now, each poised to capitalize on AI-driven advancements.The promise of AI in MedTech is substantial with workflow efficiency im ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

DexCom, Inc. (DXCM) is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist.This current Zacks Rank #3 (Hold) company’s shares have risen 6.3% year to date compared with the industry’s 10% growth. The S&P 500 Index has increased 11.5% in the same time frame.DXCM, a renowned medical device company ...

SHANGHAI, CHINA - JANUARY 25, 2022 - A 3M logo display of air-condensed thermal materials in a ... [+] shopping mall in Shanghai, China, January 25, 2022. (Photo credit should read Wang Gang / Costfoto/Future Publishing via Getty Images)Future Publishing via Getty ImagesGiven its better prospects, we believe DexCom stock (NASDAQ NASDAQ : DXCM) is a better pick than 3M stock (NYSE: MMM). Although these companies are from different sectors, we compare them because of their similar market capitalization of aro ...

Willie B. Thomas/DigitalVision via Getty Images Investment action I recommended a buy rating for Dexcom (NASDAQ:DXCM) when I wrote about it during October last year, as the 3Q23 results gave me further confidence in the business's positive outlook. The share price has rallied strongly post-my update, back to as high as DXCM’s 1-year all-time high of $142 (~10% below my target price). Based on my current outlook and analysis, I recommend a buy rating. My key update to my thesis is that DXCM should contin ...

Editor's note: Seeking Alpha is proud to welcome Nicholas Sylvia as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » JHVEPhoto I believe that DexCom is undervalued and that a price correction could occur within the next 12 months for the following reasons: Manufacturing Consolidation - I believe DexCom has the ability to s ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...